The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Wiederschain, G. Y. (2009) · Biochemistry (Moscow) · doi:10.1134/s0006297909090156 · Cited by 4,083
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 10×
“Stimulation of ECs with FGF2 or a combination of IL-10 and TGF-b1 led to reduction of SNA-reactive glyco-epitopes, as compared to resting, IL-17- or IFN-g-treated ECs (Figures 1B and 1C), suggesting that pro- or anti-inflammatory signals may either mask or unmask Gal1-specific binding sites.”
InfluentialGlycosylation in Cellular Mechanisms of Health and Disease
Ohtsubo, K., & Marth, J. D. (2006) · Cell · doi:10.1016/j.cell.2006.08.019 · Cited by 2,788
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on Angiogenesis
Benedito, R., Roca, C., Sörensen, I., Adams, S., Gossler, A., Fruttiger, M., & Adams, R. H. (2009) · Cell · doi:10.1016/j.cell.2009.03.025 · Cited by 1,107
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Autocrine VEGF Signaling Is Required for Vascular Homeostasis
Lee, S., Chen, T. T., Barber, C. L., Jordan, M. C., Murdock, J., Desai, S., Ferrara, N., Nagy, A., Roos, K. P., & Iruela-Arispe, M. L. (2007) · Cell · doi:10.1016/j.cell.2007.06.054 · Cited by 1,046
Cited by
Glycosylation in cancer: mechanisms and clinical implications
Pinho, S. S., & Reis, C. A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3982 · Cited by 3,083
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., Khoo, K.-H., Chang, S.-S., Cha, J.-H., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,091
Protein Glycosylation in Cancer
Stowell, S. R., Ju, T., & Cummings, R. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040438 · Cited by 873
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Li, C.-W., Lim, S.-O., Chung, E. M., Kim, Y.-S., Park, A. H., Yao, J., Cha, J.-H., Xia, W., Chan, L.-C., Kim, T., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.009 · Cited by 602
Consensus guidelines for the use and interpretation of angiogenesis assays
Nowak-Sliwinska, P., Alitalo, K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R., Augustin, H. G., Bates, D. O., van Beijnum, J. R., Bender, R. H. F., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9613-x · Cited by 590
Self-citationGlycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?
Mereiter, S., Balmaña, M., Campos, D., Gomes, J., & Reis, C. A. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.006 · Cited by 565
Hallmarks of glycosylation in cancer
Munkley, J., & Elliott, D. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8155 · Cited by 521
Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role
Wang, X., Bove, A. M., Simone, G., & Ma, B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.599281 · Cited by 442
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 392
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 362
The Link Between Angiogenesis and Endothelial Metabolism
Potente, M., & Carmeliet, P. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105134 · Cited by 354
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks
Peixoto, A., Relvas-Santos, M., Azevedo, R., Santos, L. L., & Ferreira, J. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00380 · Cited by 334
The galectin lattice at a glance
Nabi, I. R., Shankar, J., & Dennis, J. W. (2015) · Journal of Cell Science · doi:10.1242/jcs.151159 · Cited by 329
Galectin expression in cancer diagnosis and prognosis: A systematic review
Thijssen, V. L., Heusschen, R., Caers, J., & Griffioen, A. W. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.003 · Cited by 279
Targeting Glycosylation: A New Road for Cancer Drug Discovery
Costa, A. F., Campos, D., Reis, C. A., & Gomes, C. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.04.002 · Cited by 263
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer
Morotti, M., Bridges, E., Valli, A., Choudhry, H., Sheldon, H., Wigfield, S., Gray, N., Zois, C. E., Grimm, F., Jones, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818521116 · Cited by 131
Chen, R., Dawson, D. W., Pan, S., Ottenhof, N. A., de Wilde, R. F., Wolfgang, C. L., May, D. H., Crispin, D. A., Lai, L. A., Lay, A. R., et al. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2014.128 · Cited by 59
“The top three upstream regulators for VLTS associated proteins were vascular endothelial growth factor A (VEGFA), apolipoprotein E (APOE) and TGF-β 1, regulating 10, 9, and 24 VLTS associated proteins respectively (Figure 2B).”
Yingli, H., Ping, Y., Jun, Y., & Xingwang, Z. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167853 · Cited by 7
Metadata
- Authors
- Croci, D. O., Cerliani, J. P., Dalotto-Moreno, T., Méndez-Huergo, S. P., Mascanfroni, I. D., Dergan-Dylon, S., Toscano, M. A., Caramelo, J. J., García-Vallejo, J. J., Ouyang, J., Mesri, E. A., Junttila, M. R., Bais, C., Shipp, M. A., Salatino, M., & Rabinovich, G. A.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 156
- Issue
- 4
- Pages
- 744-758
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2134443544
- Cited by
- 505
- References
- 56
- FWCI
- 22.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.